BCAL Diagnostics (ASX:BDX) Total Assets : A$8.42 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Total Assets?

BCAL Diagnostics's Total Assets for the quarter that ended in Dec. 2023 was A$8.42 Mil.

During the past 12 months, BCAL Diagnostics's average Total Assets Growth Rate was 203.50% per year.

Total Assets is connected with ROA %. BCAL Diagnostics's annualized ROA % for the quarter that ended in Dec. 2023 was -57.33%. Total Assets is also linked to Revenue through Asset Turnover. BCAL Diagnostics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

BCAL Diagnostics Total Assets Historical Data

The historical data trend for BCAL Diagnostics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Total Assets Chart

BCAL Diagnostics Annual Data

Trend

Jun22

Jun23

Total Assets

10.59

8.37

BCAL Diagnostics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Total Assets	Get a 7-Day Free Trial			12.00	10.59	7.94	8.37	8.42

BCAL Diagnostics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

BCAL Diagnostics's Total Assets for the fiscal year that ended in Jun. 2023 is calculated as

Total Assets	=	Total Equity (A: Jun. 2023 )	+	Total Liabilities (A: Jun. 2023 )
	=	5.214	+	3.157
	=	8.37

BCAL Diagnostics's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	6.067	+	2.355
	=	8.42

BCAL Diagnostics (ASX:BDX) Total Assets Explanation

Total Assets is connected with ROA %.

BCAL Diagnostics's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-4.814	/	( (8.371	+	8.422)	/ 2 )
	=	-4.814	/	8.3965
	=	-57.33 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

BCAL Diagnostics's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0	/	( (8.371	+	8.422)	/ 2 )
=	0	/	8.3965
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

BCAL Diagnostics Total Assets Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics (ASX:BDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230

Website

https://www.bcaldiagnostics.com

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.